Sergliflozin etabonate, with the codename GW869682X and an INN and USAN designation, is an investigational anti-diabetic drug that was being developed by GlaxoSmithKline. According to its encyclopedia article it did not undergo further development after phase II. It is recorded here as an investigational compound, noted for what is held about it by its source rather than for any approved use, and the lead does not state any approval. This entry is a record of the source lead only and is not medical advice.
Facts
Drug ClassOral selective SGLT2 inhibitor 2 Mechanism of ActionImproves hyperglycemia by suppressing renal glucose reabsorption through SGLT2 inhibition 2 Mechanism of Action Classification
Approval StatusInvestigational / Clinical Trial 1 Route of Administration Connections
Sources
1. Sergliflozin etabonate (Wikipedia)
Lead paragraphQuote, Lead paragraph
is an investigational anti-diabetic drug being developed by GlaxoSmithKline
2. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice (Eur J Pharmacol 2009)
Abstract, first sentence
Sergliflozin etabonate, a novel oral selective low-affinity sodium glucose cotransporter (SGLT2) inhibitor,
Abstract, first sentence continued
improves hyperglycemia by suppressing renal glucose reabsorption, in which SGLT2 participates
Abstract, methods
after a single oral administration of sergliflozin etabonate.
View the Source3. ChEMBL: ChEMBL mechanism of action for Sergliflozin etabonate (CHEMBL450044)
ChEMBLmechanism_of_actionQuote, mechanism_of_action
Sodium/glucose cotransporter 2 inhibitor
Reader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.